The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Table 3 Clinical and biomarker characteristics obtained at baseline and follow-up of all available patients

Characteristic		No. = 133
Female gender (%)		87 (65)
Age (years)		53 (14)
RF positivity (%)		87 (65)
Baseline DAS28		5.6 (1.0)
Baseline joint damage		0.0 (0.0-0.0)
EULAR good responders (%)		50 (38)
EULAR moderate responders (%)		58 (44)
EULAR no responders (%)		24 (18)
Time-averaged DAS28		3.0 (0.9)
Radiographic progression rate		1.0 (0.0-3.4)
C2C (ng/ml)	Baseline	90 (71-124)
	1 yr	86 (70-109)
C1,2C (ng/ml)	Baseline	359 (286-427)
	1 yr	349 (269-415)
CS846 (ng/ml)	Baseline	100 (68-155)
	1 yr	113 (69-183)
CPII (ng/ml)	Baseline	335 (207-551)
	1 yr	436 (220-613)

Mean (SD) is shown for age and (baseline and time-averaged) DAS28; median (IQR) is shown for all other (non-normally distributed) continuous variables. For all categoric variables, number (%) of patients is shown. The EULAR response was determined after 6 months of treatment; time-averaged DAS28 and radiographic progression rate were calculated over 5 years of treatment; all other variables were determined at baseline unless otherwise stated. RF, rheumatoid factor; DAS28, disease activity score based on 28 joints.

ISSN: 1478-6362